New cocktail for Tough-to-Treat myeloma shows promise in early trial
NCT ID NCT04667663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of four drugs (cyclophosphamide, pomalidomide, dexamethasone, and daratumumab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination can help control the disease. Sixteen adults who have already tried at least two other therapies will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beaumont Hospital
Dublin, Ireland
-
Cork University Hospital
Cork, Ireland
-
Galway University Hospital
Galway, Ireland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- A One-Shot gene therapy could take on incurable blood cancer
- New PET tracer could sharpen diagnosis of blood cancers
- Web tool aims to empower rare cancer patients in genomic choices
- Diabetes drug metformin could boost myeloma treatment